Gossamer Bio is trading at $9.39, up 11.34%, in a move aligned with broader biotech strength.
- Biotech is up 2.10%, with industry sentiment supported by Merck KGaA’s agreed acquisition of Silence Therapeutics and positive clinical-trial news.
- Reuters reported the Merck-Silence deal on October 19.
- No clear October 20 company-specific catalyst was identified; the September FDA application and financing news are earlier developments, not a confirmed explanation for the session’s move.